The agency’s letter to the Marlborough-based medical device company's (Nasdaq: HOLX) CEO, Stephen MacMillan, which was made public on Tuesday, said the FDA found that the company’s BioZorb ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback